Hi my family,my computer has been down this last week I missed you all?much appreciated if so,c.
Hi cris, I did not know either of which you asked, but found it on Web MD. I am going to try to print it here if they let me, but look it up on WebMD. Love, Mary
Non-Hodgkin's LymphomaTools & Resources
Cancer Health CheckHow Pets Can Help Your Health Cancer and Sleep Problems What’s Your Cancer IQ?Complementary Medicine QuizHandling the Stress of Cancer
Cellular Classification of Adult Non-Hodgkin Lymphoma
Note: Some citations in the text of this section are followed by a level of evidence. The PDQ editorial boards use a formal ranking system to help the reader judge the strength of evidence linked to the reported results of a therapeutic strategy. (Refer to the PDQ summary on Levels of Evidence for more information.)
A pathologist should be consulted prior to a biopsy because some studies require special preparation of tissue (e.g., frozen tissue). Knowledge of cell surface markers and immunoglobulin and T-cell receptor gene rearrangements may help with diagnostic and therapeutic decisions. The clonal excess of light chain immunoglobulin may differentiate malignant from reactive cells. Since the prognosis and the approach to treatment are influenced by histopathology, outside biopsy specimens should be carefully reviewed by a hematopathologist who is experienced in diagnosing lymphomas. Although lymph node biopsies are recommended whenever possible, sometimes immunophenotypic data are sufficient to allow diagnosis of lymphoma when fine-needle aspiration cytology is preferred.[1,2]
Historically, uniform treatment of patients with non-Hodgkin lymphoma (NHL) has been hampered by the lack of a uniform classification system. In 1982, results of a consensus study were published as the Working Formulation. The Working Formulation combined results from six major classification systems into one classification. This allowed comparison of studies from different institutions and countries. The Rappaport classification, which also follows, is no longer in common use.
Table 1. Historical Classification Systems for Non-Hodgkin Lymphoma
Working Formulation  Rappaport Classification
A. Small lymphocytic, consistent with chronic lymphocytic leukemia Diffuse lymphocytic, well-differentiated
B. Follicular, predominantly small-cleaved cell Nodular lymphocytic, poorly differentiated
C. Follicular, mixed small-cleaved, and large cell Nodular mixed, lymphocytic, and histiocytic
D. Follicular, predominantly large cell Nodular histiocytic
E. Diffuse, small-cleaved cell Diffuse lymphocytic, poorly differentiated
F. Diffuse mixed, small and large cell Diffuse mixed, lymphocytic, and histiocytic
G. Diffuse, large cell, cleaved, or noncleaved cell Diffuse histiocytic
H. Immunoblastic, large cell Diffuse histiocytic
I. Lymphoblastic, convoluted, or nonconvoluted cell Diffuse lymphoblastic
J. Small noncleaved-cell, Burkitt, or non-Burkitt Diffuse undifferentiated Burkitt or non-Burkitt
As the understanding of NHL has improved and as the histopathologic diagnosis of NHL has become more sophisticated with the use of immunologic and genetic techniques, a number of new pathologic entities have been described. In addition, the understanding and treatment of many of the previously described pathologic subtypes have changed. As a result, the Working Formulation has become outdated and less useful to clinicians and pathologists. Thus, European and American pathologists have proposed a new classification, the Revised European American Lymphoma (REAL) classification.[5,6,7,8] Since 1995, members of the European and American Hematopathology societies have been collaborating on a new World Health Organization (WHO) classification, which represents an updated version of the REAL system.[9,10,11]
Blood Test May Reveal Lymphoma Dangers
Burkitt Lymphoma: Diagnosis, Prognosis, Symptoms, and Treatments
Diagnosis & Treatment for Non-Hodgkin's Lymphoma
Symptoms of Non-Hodgkin's Lymphoma
What is Non-Hodgkin's Lymphoma?
Lymphoma,Gastric,Non Hodgkins Type
Mantle Cell Lymphoma
See All Lymphoma Topics
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 Next Page > WebMD Public Information from the National Cancer
Candbeseen (love that name),
Did some research online and have come up with some relatively good news, lemme go and find it (brb). Lymphomatoid Papulosis is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the mildest of the indolent, cutaneous t-cell lymphomas. These lesions are actually benign (not harmful), although they have T-cells that resemble abnormal tumors in lymphomas. Most patients don’t have lymphoma when they are diagnosed with this conditon; only 20% of patients with lymphomatoid papulosis develop more extensive lymphoma at any point in their lifetime (before, during, or after diagnosis). The incidence of this disease in the United States is 1.9 cases per one million people, so it is extremely rare. Hodgkin’s disease, mycosis fungoides, and large cell lymphoma are associated with the disease for patients who are, in fact, diagnosed with lymphoma.
Patients present with raised bumps on the skin that may develop into blood or pus-filled blisters. These papules (lesions) may become crusty or itchy. They are usually found on the chest, back, stomach, arms or legs. Lesions usually heal on their own within a few weeks of their appearance, and they leave behind no visual scarring.
A diagnosis is made via skin biopsy. The lesions may be type A, type B, or type C, depending on their appearance.
Since these lesions typically heal on their own, there is no cure for the disease. Some topical treatments have been used in clinical trials, as well as the chemotherapy agent methotrexate. However, these treatments only ease symptoms until the body heals on its own. This can take several years.
Cancer Patients have more options through clinical studies. Follow this link to learn more and find a clinical study opportunity near you
Toll Free: 1.800.383.6610
That is the information I found from Pharmtech Oncology
Clinical studies are research studies that test how well new medical approaches work in people. The goal of oncology studies is to find better ways to treat cancer and improve the overall standard of cancer care.
Clinical studies take place in doctors’ offices, cancer centers, other medical centers, community hospitals and clinics, and veterans’ and military hospitals across the U.S. and throughout the world. The results of clinical studies are often published in peer-reviewed, scientific journals. Once a new approach has been proven safe and effective in a clinical study, it may become standard practice.
Every clinical study has a protocol, or action plan. The plan describes:
•What will be done in the study
•How the study will be conducted
All clinical studies that are federally funded or that evaluate a new drug or medical device that is subject to U.S. Food and Drug Administration regulation must be reviewed and approved by an Institutional Review Board (IRB). These Boards, which include doctors, researchers, community leaders, and other members of the community, review the protocol to make sure the study is conducted fairly and participants are not likely to be harmed.
Informed consent is a process by which people learn the important facts about a clinical study to help them decide whether or not to participate. This information includes details about:
•the purpose of the study
•the tests and other procedures used in the study
•the possible risks and benefits.
In addition to talking with the doctor or nurse about the study, potential participants receive a written consent form explaining the study.
People who agree to take part in the study are asked to sign the informed consent form. However, signing the form does not mean people must stay in the study. People can leave the study at any time—either before the study starts or at any time during the study or the follow-up period.
The informed consent process continues throughout the study. If new benefits, risks, or side effects are discovered during the study, the researchers must inform the participants. They may be asked to sign new consent forms if they want to stay in the study.
Clinical studies are usually conducted in a series of four steps, called phases:
Phase I studies: These initial studies evaluate how a new drug should be given (by mouth, injected into the blood, or injected into the muscle), how often, and what dose is safe. A Phase I study usually enrolls only a small number of participants.
Phase II studies: These studies continue to test the safety of the drug, and begin to evaluate how well the new drug works. Phase II oncology studies usually focus on a particular type of cancer.
Phase III studies: These studies test a new drug, a new combination of drugs, or a new surgical procedure in comparison to the current standard. A participant will usually be assigned to the standard group or the new group at random (called randomization). Phase III studies often enroll large numbers of people and may be conducted at many doctors' offices, clinics, and cancer centers nationwide.
Phase IV studies. After a treatment has been approved and is being marketed, the drug's maker may study it further to evaluate the side effects, risks, and benefits of a drug over a longer period of time. Thousands of people are involved in a phase IV study.
There are both benefits and risks to participating in clinical studies. Among the benefits:
•You may gain access to promising new approaches that are often not available outside the clinical study setting.
•You may have access to an approach or drug that may be more effective than the standard approach.
•You may receive regular and careful medical attention from a research team of doctors, nurses and other health professionals. You may be among the first to benefit from the new method under study.
•You will have the satisfaction of knowing that results from the study may help others in the future.
Among the risks:
•The new drug or approach under study may not be better than the standard care to which it is being compared.
•You may experience side effects that doctors could not anticipate or that are worse than those resulting from standard care.
•In randomized studies, you will not be able to choose the approach you receive.
•Health insurance and managed care providers may not cover all of the study costs.
You may be required to make more visits to the doctor than you would if you were not in a clinical study.
Well sweetness, that's what I found at one site and I have acess to health careprovider stuff too, so I will research this until you tell m to stop. If you need me to look up anything in particular and you can't find it, I'll go tomy secret spot and get as much of the newest info I can get.
I'll be praying my hippie prayers to my God for your family, Candbeseen,
Hippie Love, Hugs and Kisses All Around,
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Posted 4 Jul 2010 • 6 answers
Posted 21 Jul 2010 • 24 answers
Posted 20 Nov 2010 • 7 answers
Posted 8 Apr 2011 • 2 answers
Posted 1 Dec 2012 • 4 answers